| Description: |
Noggin is part of a group of soluble proteins that bind to ligands from the TGF-β family, regulating their activity by blocking access to signaling receptors. This interaction plays a critical role during development, where the cellular response can vary significantly depending on the local concentration of the signaling molecules. Initially identified as an antagonist of BMP-4, noggin is essential for the proper formation of the head and other dorsal structures. It also modulates the activities of other BMPs such as BMP-2, BMP-7, BMP-13, and BMP-14.
In mice, targeted deletion of the noggin gene leads to prenatal death and a recessive phenotype characterized by severe skeletal malformations. Conversely, transgenic mice that overexpress noggin in mature osteoblasts exhibit impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.
Recombinant Human Noggin is a disulfide-linked homodimer weighing 46 kDa, composed of two 205 amino acid polypeptide chains. In SDS PAGE analysis under reducing conditions, glycosylated monomeric noggin typically migrates at an apparent molecular weight ranging from 28.0 to 33.0 kDa. |
| Source: |
HEK293 cells |
| Purity: |
≥ 95% by SDS-PAGE gel and HPLC analyses. |
| AA Sequence: |
QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC |
| Predicted Molecular Mass: |
46 kDa |
| Biological Activity: |
Determined by its ability to inhibit 5.0 ng/mL of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 2.0-3.0 ng/mL of Noggin. |
| Endotoxin: |
Endotoxin level is < 0.1 ng/μg of protein (< 1 EU/μg) |
| Crossreactivity: |
Chicken, dog, human, human + mouse, mouse, rat |
